Latest Insider Transactions at Collegium Pharmaceutical, Inc (COLL)
This section provides a real-time view of insider transactions for Collegium Pharmaceutical, Inc (COLL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of COLLEGIUM PHARMACEUTICAL, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of COLLEGIUM PHARMACEUTICAL, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,657
-3.15%
|
$222,111
$23.38 P/Share
|
|
Apr 01
2021
|
Richard Malamut EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,119
-3.23%
|
$71,737
$23.38 P/Share
|
|
Mar 30
2021
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,984
+3.72%
|
-
|
|
Mar 16
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-0.75%
|
$17,616
$24.69 P/Share
|
|
Mar 15
2021
|
Michael Thomas Heffernan Director |
SELL
Open market or private sale
|
Direct |
50,075
-64.87%
|
$1,251,875
$25.57 P/Share
|
|
Mar 01
2021
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
64,768
-9.71%
|
$1,424,896
$22.93 P/Share
|
|
Mar 01
2021
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
48,616
+12.41%
|
$388,928
$8.22 P/Share
|
|
Mar 01
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
6,011
-3.88%
|
$138,253
$23.36 P/Share
|
|
Feb 11
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,898
-4.41%
|
$197,450
$25.11 P/Share
|
|
Feb 10
2021
|
Richard Malamut EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,300
-1.17%
|
$57,500
$25.95 P/Share
|
|
Feb 10
2021
|
Paul Brannelly Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,491
-1.91%
|
$212,275
$25.95 P/Share
|
|
Feb 10
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,786
-3.8%
|
$594,650
$25.95 P/Share
|
|
Feb 10
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,144
-2.21%
|
$178,600
$25.95 P/Share
|
|
Feb 10
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,858
-2.87%
|
$146,450
$25.95 P/Share
|
|
Feb 10
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,184
-2.72%
|
$129,600
$25.95 P/Share
|
|
Jan 20
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
6,081
-5.55%
|
$145,944
$24.45 P/Share
|
|
Jan 19
2021
|
Joseph Ciaffoni President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
133,989
+17.49%
|
-
|
|
Jan 19
2021
|
Paul Brannelly Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
50,161
+9.91%
|
-
|
|
Jan 19
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
52,132
+18.21%
|
-
|
|
Jan 19
2021
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,889
+13.14%
|
-
|
|
Jan 19
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,945
+19.84%
|
-
|
|
Jan 19
2021
|
Richard Malamut EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,147
+14.9%
|
-
|
|
Jan 15
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,322
-2.89%
|
$29,084
$22.89 P/Share
|
|
Jan 11
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
701
-1.51%
|
$14,721
$21.18 P/Share
|
|
Jan 07
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
16,042
-12.59%
|
$352,924
$22.0 P/Share
|
|
Jan 07
2021
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,042
+11.18%
|
$80,210
$5.73 P/Share
|
|
Jan 04
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,090
-0.59%
|
$21,800
$20.03 P/Share
|
|
Dec 03
2020
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
5,967
-5.08%
|
$113,373
$19.24 P/Share
|
|
Nov 30
2020
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,672
-2.46%
|
$84,096
$18.49 P/Share
|
|
Nov 18
2020
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+12.0%
|
$80,000
$5.73 P/Share
|
|
Oct 15
2020
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,060
-10.93%
|
$141,200
$20.82 P/Share
|
|
May 10
2018
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
1,400
-0.9%
|
$37,800
$27.0 P/Share
|
|
Jan 19
2018
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
6,660
-1.25%
|
$153,180
$23.0 P/Share
|
|
Jan 19
2018
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,660
+1.23%
|
$13,320
$2.71 P/Share
|
|
Jan 12
2018
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-2.33%
|
$157,500
$21.0 P/Share
|
|
Jan 12
2018
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+2.26%
|
$0
$0.69 P/Share
|